HERON THERAPEUTICS, INC. /DE/·4

Apr 21, 11:15 AM ET

Forbes William P 4

Research Summary

AI-generated summary

Updated

Heron Therapeutics (HRTX) EVP William P. Forbes Converts 3,874 RSUs

What Happened
William P. Forbes, EVP and Chief Development Officer at Heron Therapeutics (HRTX), had 3,874 restricted stock units converted into 3,874 shares on April 19, 2026 (reported on Form 4 filed 2026-04-21). The filing shows an acquisition via exercise/conversion (code M) of 3,874 shares (acquisition price N/A) and a simultaneous disposition of 3,874 shares at $0.00 (no cash proceeds reported).

Key Details

  • Transaction date: 2026-04-19; Form 4 filed: 2026-04-21 (appears timely under Section 16 reporting rules).
  • Acquisition: 3,874 shares via exercise/conversion (price listed as N/A).
  • Disposition: 3,874 shares at $0.00 (no proceeds reported).
  • Shares owned after transaction: not specified in the provided filing excerpt.
  • Footnotes: F1 — each restricted stock unit (RSU) equals one share; F2 — RSUs vest in 16 equal quarterly installments beginning 01/19/2024.
  • Transaction code M indicates exercise or conversion of a derivative (here, RSUs).

Context
This appears to be a routine RSU vesting/conversion event. Filings that show converted RSUs alongside a zero-dollar disposition commonly reflect shares transferred to satisfy tax withholding or company obligations, though the Form 4 excerpt does not explicitly state tax withholding. Such conversions are not the same as open-market purchases or sales and typically do not signal a directional trade by the insider.